Evaluating the safety and efficacy of oocyte and embryo vitrification for fertility preservatio
- Conditions
- Cancer, Hematologic disease, Immune disorders
- Registration Number
- JPRN-UMIN000028909
- Lead Sponsor
- Keio University
- Brief Summary
Gonadotoxic treatment resulted in fewer oocytes. Although anti-Mullerian hormone levels were lower in the post-gonadotoxic treatment group than in the pre-gonadotoxic treatment group, oocyte maturation rates were higher in the post-gonadotoxic treatment group than in the pre-gonadotoxic group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 43
Not provided
1. Freezing 1) The patients who cannot realize or obtain informed consent. 2) The patients judged to be inappropriate for the study by the physicians. 3) The case to delay treatments because of fertility preservation. 2. Fertilization, Embryo Transfer 1) Unmarried patients. 2) The patients who are more than 50 years old. 3) The patients undergoing hysterectomies. 4) The patients whose cancers, hematological diseases, or immune disorders have progressed at the time of embryo transfer.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival rate of oocytes and embryos after freezing and thawing
- Secondary Outcome Measures
Name Time Method Total dose of gonadotropins, Oocytes retrieval number, Total number of mature oocytes, Fertilization rate, Blastocyst development rate, The ratio of embryos available for transfer per oocyte pick up, Implantation rate per embryo transfer, Liver birth rate per oocyte pick-up